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Abstract
Non-alcoholic fatty liver disease (NAFLD) can develop cirrhosis and even hepatocellular 
carcinoma, resulting in a high liver-related morbidity and mortality, being important to 
know those risk factors for disease progression, among which the presence of diabetes 
stands out. In addition, it is a disease with multisystemic behavior, becoming an indepen-
dent risk factor for cardiovascular disease and extrahepatic tumors. Hence, early diagno-
sis and multidisciplinary management of NAFLD are really important. In this chapter, 
we will expose the different diagnostic and follow-up tools available for this disease, and 
with them we will make an algorithm according to the recommendations and the current 
evidence.
Keywords: NAFLD, biomarkers, transient elastography, multisystemic disease
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver damage whose 
distinctive feature is the accumulation of intrahepatic fat, especially triglycerides, which can-
not be attributed to secondary causes such as alcohol and certain drugs. NAFLD is nowadays 
considered to be the most common cause of chronic liver disease in western countries, show-
ing a prevalence of around 30% in the general population [1]. Within NAFLD, two histo-
logical subtypes can be distinguished: (a) non-alcoholic fatty liver (NAFL), which includes 
patients with simple steatosis with or without mild inflammation and (b) non-alcoholic ste-
atohepatitis (NASH), characterized by the presence of hepatic inflammation and hepatocyte 
injury (ballooning) with or without fibrosis [2, 3]. NAFL is a generally benign condition, and 
NASH is the progressive subtype that can lead to cirrhosis and hepatocellular carcinoma 
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(HCC) [4]. However, several studies with paired liver biopsies have demonstrated that both 
patients with NASH and those with NAFL have the potential to develop a progressive hepatic 
disease, and in this risk of progression there are some key factors such as diabetes mellitus 
[5, 6]. In general, patients with NAFLD have a higher long-term mortality than the general 
population, cardiovascular disease (CVD) being the principal cause of death, followed by 
different types of cancer [7–9] and liver-related complications, as well as the cardiovascular 
risk caused by the different factors of the metabolic syndrome, very frequent in this type of 
subjects; NAFLD is itself an independent risk factor for CVD [10]. Liver-related mortality is 
increased up to 10-fold in patients with NAFLD. In this sense, it should be emphasized that 
cirrhosis and HCC are the fifth most prevalent cause of mortality in the world. Therefore, 
given the hepatic and cardiovascular morbi-mortality generated by NAFLD, the early iden-
tification of these patients is important to provide suitable management that can lower the 
mortality for all causes.
2. Screening and diagnostic criteria
The mechanisms leading to the development and progression of NAFLD are not completely 
known, but it is widely accepted that the initial events are dependent on the development of 
obesity and insulin resistance (IR) [11]. For this reason, NAFLD has a strong association with 
the factors constituting the metabolic syndrome, the prevalence in this group of patients being 
considerably heightened. This relation is especially close in morbid obesity, where NAFLD 
is present in more than 90% of the cases, this condition taking the form of steatohepatitis in 
a third of the cases, while in up to 5–10% of the subjects, the liver disease has progressed to 
cirrhosis [12, 13]. The association between NAFLD and IR or diabetes mellitus type 2 (DM2) 
has also been clearly established [14]. It has been demonstrated that DM2 is associated with a 
greater hepatic content of triglycerides independently of the body mass index (BMI) [15, 16]. 
Thus, the prevalence of NAFLD in DM2 patients can reach up to 70% [11, 17, 18]. Moreover, 
both prediabetes (glucose intolerance and altered glucose when fasting) and DM2 are related 
to the severity of liver damage, the presence of steatohepatitis, fibrosis and even HCC [1, 19, 
20]. Overall, 80% of the NAFLD cases present with some of the cardiovascular risk factors that 
constitute the metabolic syndrome (IR, obesity, dyslipidemia and arterial hypertension), and 
its prevalence directly increases the number of these factors that are present [21].
As a consequence of its high prevalence, especially in subjects with the abovementioned risk 
factors, its prognostic implications, and given that NAFLD is generally an asymptomatic dis-
ease, some authors recommend the implantation of an NAFLD-screening programme within 
the risk population [22, 23]. However, this topic is at present controversial given the great 
load on the national health systems that could be caused by these screening programmes and 
the lack of efficacious treatments currently available. In fact, the principal associations for 
the study of liver diseases (American Association for the Study of Liver Diseases (AASLD) 
and European Association for the Study of the Liver (EASL)) in their guidelines for clinical 
practice do not recommend this screening in any population [24] or they recommend it, with 
an A2 level of evidence, only for patients with DM2 independently of the levels of hepatic 
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enzymes [25]. To attempt to answer this question, valid cost-utility studies are necessary in 
screening programmes. There is no discussion, however, about the need to act when faced 
with a patient suspected of having NAFLD and not to underestimate its discovery due to the 
limited clinical and analytical repercussion manifested at first. In our opinion, patients with 
NAFLD and suspected to have advanced disease must be evaluated in specialist units for 
their correct characterization in case of a prompt availability of specific treatment.
2.1. Clinical and analytical manifestations
A diagnosis of NAFLD is very often reached through a casual analytical discovery during 
a health examination after an alteration in tests of liver function, or an alteration in hepatic 
morphology detected through an image study done with another objective, given that it is 
generally an asymptomatic disease. In the cases in which the patient reports symptoms, they 
are usually mild and unspecific, asthenia and abdominal problems being frequent, especially 
in the right hypochondria. The physical exploration may be normal or detect a soft, painless 
hepatomegaly, although occasionally it is difficult to evaluate as these patients very often 
present with central-type obesity, and in the patients with advanced fibrosis and cirrhosis, we 
may find signs of portal hypertension such as ascites, splenomegaly or jaundice [26].
Analytically, most of the patients present tests with normal or discretely altered liver func-
tion, with a predominance of ALT (alanine aminotransferase) compared to AST (aspartate 
aminotransferase). On specific occasions, a discrete elevation can be appreciated in the mark-
ers of cholestasis, especially GGT (gamma-glutamyl transpeptidase), which has been related 
to obesity and IR [27]. Another frequent analytical discovery is the elevation of the levels of 
ferritin in blood and of the transferrin saturation index without having demonstrated a cor-
responding increase in the deposits of hepatic iron [28]. Something similar occurs with the 
presence of elevated autoantibodies, which appear quite frequently in NAFLD and are con-
sidered an epiphenomenon [29].
2.2. Diagnosis of steatosis
Hepatic steatosis is defined histologically as the deposit of fat ≥5% of the hepatocytes and is 
classified in four grades depending on the percentage of hepatocytes with steatotic vacuoles. 
The normal liver (S0) contains fat in less than 5% of the hepatocytes while grade 1 steatosis 
(S1) corresponds to less than 33% of the steatotic hepatocytes. In grade 2 and 3 steatosis, fat is 
present in at least 33 or 66% of the hepatocytes, respectively.
The presence of risk factors such as DM2, metabolic syndrome and obesity with the eleva-
tion of the hepatic enzymes, especially ALT, increases the possibility of fatty liver presenting. 
Nevertheless, although the ALT is a useful test, it is not valid for predicting the presence 
of this disease, or even the risk of progression, given that it can occur with normal hepatic 
enzymes [30]. In fact, in patients with DM2 and normal levels of ALT, a high prevalence of 
NAFL and NASH has been reported [31].
In clinical practice, ultrasound scan is a first-rate image technique if NAFLD is suspected 
due to its wide availability, low cost and safety [32]. The sensitivity of this technique is 93% 
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when the steatosis is greater than 33%; however, this sensitivity decreases considerably when 
the steatosis affects less than 30% of the hepatocytes [33, 34]. Steatosis can also be diagnosed 
through computerized tomography (CT), but its cost and the patient’s exposure to radiation 
make its systematic use in long-term follow-up unadvisable in this pathology; moreover, its 
sensitivity does not improve substantially if the steatosis is mild [32]. Magnetic resonance 
imaging (MRI), including spectroscopy, can diagnose content levels of hepatic fat >5% and it 
is reliable to determine changes (≥0.5%) in the grade of steatosis after weight loss. Although 
its use has widened in many studies, its use in clinical practice is limited by its cost and dura-
tion [35, 36].
The recently developed CAP (controlled attenuation parameter), an application of transient 
elastography (TE), which will be discussed later, available in the latest generation devices, 
enables the immediate and easy quantification of steatosis. CAP measures the degree of 
attenuation of the ultrasound wave transmitted through the liver, which is proportional to 
the amount of hepatic fat, and is less influenced by the sampling error than the liver biopsy, 
since it explores a liver volume approximately 100 times greater. Its values oscillate between 
100 and 400 dB/m and it is possible to measure the liver stiffness used for the evaluation of 
fibrosis simultaneously. The studies published to date indicate that CAP is capable of diag-
nosing steatosis in chronic liver diseases of diverse causes even in mild stages (>10%) and has 
a good correlation with the degree of steatosis [37–44]. These studies show different cut-offs 
of CAP for the different grades of steatosis, but all of them demonstrate that the cut-offs do 
not differ among the different causes of liver diseases, in contrast with what happens with 
transient elastography [40]. In this sense, a recent meta-analysis including 2735 patients has 
established a series of cut-offs for the different grades of steatosis: 248 dB/m for S1, 268 dB/m 
for S2 and 280 dB/m for S3, with a sensitivity of 69, 77 and 88%, respectively, and a specificity 
of 82, 81 and 78%, respectively. In this meta-analysis, etiology, BMI and diabetes showed a 
significant influence on the value of the CAP, so the authors suggested the cut-offs established 
but subtracting 10 dB/m from the value of the CAP for the patients with NAFLD, 10 dB/m for 
diabetics, and subtracting/adding 4.4 dB/m for each unit of BMI above/below 25 kg/m2 in the 
interval of 20–30 kg/m2 [45].
Another image technique is magnetic resonance imaging-estimated proton density fat frac-
tion (MRI-PDFF), which is based on chemical shift-based water fat separation methods. MRI-
PDFF has shown good correlation with histology-determined steatosis grade in NAFLD 
patients, so it could be used for follow-up and treatment-response evaluation [46].
Lastly, within the non-invasive diagnosis of steatosis, various serological tests of biomark-
ers have been developed to predict the existence of hepatic fat (Table 1) [47–51]. However, 
all these biomarkers may be influenced by inflammation and fibrosis, and given that they 
do not provide great advantages compared to image techniques and routine analysis, their 
use in clinical practice is not widespread; even so, the Fatty Liver Index (FLI) that uses eas-
ily available parameters could be considered, although CAP has demonstrated better perfor-
mance than this test for the diagnosis of grade 2–3 steatosis [44]. Nevertheless, FLI has been 
associated independently to liver-related mortality, as well as to the mortality rates due to 
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 cardiovascular disease and cancer, but it seems that these associations are interfered by the 
risk conferred by the state of insulin resistance [52].
When steatosis is suspected in the aforementioned non-invasive methods, the liver biopsy 
is still the gold-standard method to conclusively diagnose NAFLD and the only one capable 
of distinguishing between NAFL and NASH, thus enabling the classification of the disease 
Indices Formula Cut-offs Sensitivity (%) Specificity (%)
Hepatic 8 × ALT/AST ratio + BMI 30 (low cut-off) 93 40
Steatosis (+2, if DM; +2, if female) 36 (high cut-off) 45 93
Index (HSI)
Fatty liver exp(n)/1 + exp (n) × 100 10 (low cut-off) 95 29
Index (FLI) (n) = 0.953 × ln(TG) +
0.139 × BMI + 0.718 ×
60 (high cut-off) 44 91
ln(GGT) + 0.053 × waist
circumference – 15.745
SteatoTest Proprietary formula 0.3 (low cut-off) 90 54
(a2-macroglobulin, 0.7 (high cut-off) 46 88
haptoglobin,
apolipoprotein A1, GGT,
bilirubin, ALT,
cholesterol, triglycerides,
glucose, BMI, age,
gender)
NAFLD liver −2.89 + 1.18 × metabolic −0.640 86 71
Fat score Syndrome (yes: 1, no: 0)
+ 0.45 × Type 2 diabetes
(yes: 2, no: 0) + 0.15 ×
insulin + 0.04 × AST −
0.94 × AST/ALT
Lipid LAP (men) = Waist 20 (low cut-off) 99 16
accumulation circumference – 65 80 (high cut-off) 43 94
product (LAP) LAP (women) = Waist
circumference − 58
Table 1. Indices for diagnosis of steatosis.
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according to the grade of activity (inflammation and hepatocyte injury) and the stage of fibro-
sis, the best predictors of the disease progression [53, 54]. The advantages and, especially, the 
drawbacks of the liver biopsy are dealt with later.
2.3. Initial diagnosis of NAFLD
From what has been mentioned so far, we can specify a series of characteristics that indicate 
a patient with NAFLD: (1) radiological evidence of steatosis or CAP >248 dB/m ± Abnormal 
liver blood test, (2) the presence of insulin resistance or another component of the metabolic 
syndrome, (3) consumption of alcohol of <30 g/d in men and <20 g/d in women and (4) exclu-
sion from other causes of chronic liver disease (viral hepatitis, cholestatic diseases, autoim-
mune hepatitis, hemochromatosis, α1 antitrypsin deficiency, Wilson’s disease, drug-induced 
liver injury and celiac disease) [24, 25]. Once the initial diagnosis of NAFLD has been made, 
our next step is to evaluate the stage of disease and the necessity of carrying out a liver biopsy.
3. Diagnosis of steatohepatitis
A key element in the diagnosis of NAFLD is the differentiation of NASH from NAFL and the 
staging of the liver fibrosis, given that patients with NASH and advanced fibrosis are those 
at the greatest risk of developing hepatic complications and cardiovascular disease [54–56].
3.1. Liver biopsy
As it was mentioned earlier, the chosen method to evaluate the grade of histological lesion 
is still the liver biopsy. However, liver biopsy has well-known limitations and cannot be 
proposed for all patients, given the high prevalence of NAFLD worldwide. Liver biopsy is 
invasive and is not without complications. Besides, there are other drawbacks: (1) sampling 
error, since a typical liver biopsy samples only 1/50,000 of all liver tissues, and histolog-
ical lesions of NASH are unevenly distributed throughout the liver parenchyma [57]; (2) 
inter- and intra-observer variability, as observed by Gawrieh et al. although there was a high 
agreement ratio in the assessment of steatosis grading and fibrosis staging between patholo-
gists, the agreement was suboptimal for lobular inflammation and hepatocellular ballooning 
[58]; and (3) the existence of different criteria for the definition of NASH. The Non-alcoholic 
Steatohepatitis Clinical Research Network (NASH-CRN) proposed the system termed the 
NAS scoring system in order to classify NAFLD according to severities of fatty change, 
inflammation and hepatocellular ballooning [3]. NAS is markedly reproducible and is useful 
for assessing therapeutic effects in Clinical trials, but it is incapable of diagnosing NASH in 
patients with burned-out NASH, in whom fatty changes and inflammatory cell infiltration 
resolving in fibrosis have progressed [59].
Given these limitations, non-invasive methods have been developed for the diagnosis of 
NASH and fibrosis as a first option to examine NAFLD patients and to help determine which 
require a liver biopsy. The ideal test should be economical, reproducible and capable of 
diagnosing the whole spectrum of lesions, including within NAFLD, and even reflecting the 
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changes produced on initiating specific treatment. Nowadays, we do not have a test available 
that has these characteristics, so these non-invasive methods are based on diverse comple-
mentary approaches: clinical factors, genetics, serological markers, image tests and transient 
elastography [60, 61].
3.2. Risk factors associated with non-alcoholic steatohepatitis and progressive disease
The best predictor of the evolution of NAFLD is the presence of necroinflammation and 
fibrosis in liver biopsy; however, there are more and more studies reporting no insignificant 
rates of progression of simple steatosis [5, 6, 62]. A first study that analyzed patients with 
NAFLD and paired biopsies demonstrated that even patients with simple steatosis can prog-
ress to NASH and advanced fibrosis, especially in the presence of metabolic risk factors [6]. 
Therefore, there is a series of non-modifiable and modifiable factors in patients associated 
with a greater risk of development of NASH and more progressive disease.
Various transversal studies have demonstrated that the disease is more severe in older patients, 
although this phenomenon could be due to the sum of pathogenic factors and a greater duration 
of the liver disease itself and the associated diseases [8, 63, 64]. In fact, the longitudinal studies 
have not managed to demonstrate that age is a factor that aggravates the disease per se [65]. 
The association between sex and fibrosis progression is controversial; two transversal studies 
show that men and post-menopause women have a greater risk of fibrosis in comparison with 
pre-menopause women; moreover, precocious menopause is associated with a greater risk of 
fibrosis [66–69]. Other non-modifiable factors are genetic; dozens of genes with multiple poly-
morphisms associated with NAFLD have been discovered thanks to genome-wide association 
studies (GWAS), but the number of strongly validated genes in large independent cohorts is 
limited to two, patatin-like phospholipase domain containing 3 (PNPLA3) and transmembrane 6 super-
family member 2 (TM6SF2) [70]. The presence of the single nucleotide polymorphisms (SNPs) 
rs738409 and rs58542926 of the genes PNPLA3 and TM6SF2, respectively, has been associated 
with a greater risk of NAFLD, as well as a more severe disease [71–76]. Recently, an SNP of 
IL28b (also implicated in the response to interferon in chronic hepatitis C patients (VHC)) has 
been associated with an increment in fibrosis in NAFLD patients [77]. Moreover, in a control-
case study carried out by our working group, we have observed that the presence of the variants 
rs1421085 and rs1558902 of the fat mass and obesity-associated (FTO) gene confer a high risk of 
liver inflammation particularly in patients of normal weight with NAFLD (unpublished).
On the other hand, NAFLD tends to be more severe in patients with various factors of 
the metabolic syndrome, particularly DM2 and obesity. In fact, the reduction in weight 
and good glycemic control are associated with an improvement in inflammation and liver 
fibrosis [11, 78, 79]. However, it is known that NASH can also be present in slim subjects 
although it is unknown whether the natural history of the disease in these slim subjects is 
similar to that present in obese subjects. As for arterial hypertension, it is arguable whether 
its treatment improves the histology of NASH [5, 80]. Another factor of the metabolic 
syndrome, frequent in NAFLD patients, is dyslipidemia, fundamentally in the form of 
hypertriglyceridemia and atherogenic dyslipidemia [64, 81]; but moreover, a recent study 
has related the very low-density lipoprotein (VLDL) profile with the NAFLD severity, 
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observing that a decrease in small VLDL particle concentration is associated with more 
advanced fibrosis [82]. Vitamin D deficiency is also frequent among NAFLD patients, and 
its levels have been correlated negatively with the severity of steatosis, inflammation and 
fibrosis [83, 84].
Another possible factor associated with NAFLD progression is the alcohol consumption, a 
controversial aspect as despite there being a limit above which the consumption of alcohol 
would define alcoholic steatohepatitis (≥ 60 g/d in women and ≥80 g/d in men), it is not clear 
that we are confronting a pathology different to NASH given that the pathogeny of these enti-
ties presents a great similarity. Moreover, the quantification of alcohol consumption is quite 
subjective, imprecise, habitually underestimated and not contrasted with objective determina-
tions through biomarkers. At present, there is no agreement on the impact of light- moderate 
consumption of alcohol on NAFLD given that the literature available about this topic shows 
contradictory results relate to NAFLD progression [85, 86]. Nevertheless, it seems that all the 
relevant studies are in favor of a possible benefit from the moderate alcohol consumption, 
defined as the consumption of up to one drink a day for women and two drinks a day for men 
[87]. While the consumption of large doses of alcohol leads to the development of insulin resis-
tance and to the infiltration of macrophages into the adipose tissue [88], moderate consumption 
has been associated with an improvement in the sensitivity to insulin and high concentrations 
of adiponectin [89–91]. Various studies suggest a significant association between the moderate 
consumption of alcohol and the less histological severity of NAFLD [92, 93]. As for the develop-
ment of HCC, only one prospective study exists that evaluates the consumption of alcohol with 
the risk of HCC in NAFLD, finding a greater risk of this tumor with moderate use of alcohol; 
however, this study is carried out in patients with cirrhosis due to established NASH, without 
evaluating the impact of alcohol on patients with a less severe disease [94].
3.3. Non-invasive diagnosis of non-alcoholic steatohepatitis
There is still no available image test in clinical practice capable of differentiating NAFL from 
NASH, so various biomarkers have been evaluated to predict the existence of NASH, which 
are related to pathogenesis pathways of the disease (apoptosis/cellular death, inflammation 
and oxidative stress).
The most studied serum biomarker associated with the presence of NASH is cytokeratin 18 
fragments (CK18-F), a product of the degradation resulting from the apoptosis of hepato-
cytes mediated by caspase 3 [95], which is measured using enzyme-linked immunosorbent 
assay (ELISA). Various studies have demonstrated a significant increase in CK18-F in NASH 
patients in comparison with NAFL patients, and a positive correlation with fibrosis and the 
histological components of NASH [96, 97]. However, the sensitivity and specificity of this test 
are quite low, around 60% [98]. Oxidized low-density lipoprotein (LDL), thiobarbituric acid 
reactive substances (TBARS) and malonaldehyde have been used as markers of oxidative 
stress, but the results are contradictory [99, 100]. Among the markers of inflammation stud-
ied include leptin, protein C reactive, interleukin 6, hyaluronic acid, adiponectin and tumor 
necrosis factor α (TNFα). All of them have been evaluated in short series or pilot studies in 
heterogeneous groups of patients with contradictory results [101].
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With the aim of improving the diagnostic value of the biomarkers, predictive models have 
been developed that combine some of these serum biomarkers with analytical parameters 
and clinical variables, but they have not been adequately validated, so up to now, they are not 
recommendable in clinical practice [102–107] (Table 2).
3.3.1. Emerging fields
Emerging fields in the search for non-invasive biomarkers of NAFLD are proteomics, metabo-
lomics and epigenetics.
Proteomics provides essential information about the biologically active entity named pro-
tein. Thanks to proteomic analysis, key changes in serum protein expression levels have been 
demonstrated between control subjects and patients with different stages of fatty liver [108].
In the last years, studies about the use of metabolomic to discover biomarkers of progression 
of NAFLD have received great interest, and not only in this liver disease [109–111]. In fact, a 
Spanish group has developed the so-called OWL Liver Test that consists in the determination 
Model Variables Sensitivity (%) Specificity (%)
HAIR score Hypertension, ALT, insulin 80 89
resistance
NASHTest Age, gender, weight, 88 50
height, cholesterol,
triglycerides, α2-
macroglobulin,
apolipoprotein A1,
haptoglobin, GGT, ALT,
AST, bilirubin
NASH score PNPLA3 genotype, insulin, 75 74
AST
Nice model Ck18, ALT, metabolic 84 86
syndrome
NAFLD Diabetes, gender, BMI, 91 47
diagnostic triglycerides, M30, M65-
panel M30
OxNASH Age, BMI, AST, 13- 81 –
Hydroxyoctadecadienoic
acid, linoleic acid
Table 2. Predictive models for non-alcoholic steatohepatitis.
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of more than 500 serum metabolites through liquid chromatography coupled with mass spec-
trometry (LC–MS) in NAFLD patients obtaining a metabolomic profile that enables the dif-
ferentiation between NAFL and NASH with good specificity and sensitivity [112]. Moreover, 
the same group thanks to the study of metabolomic profiles at the serum level observed two 
different subtypes of NAFLD according to the involvement of the methionine metabolism, 
subtype M and subtype no M, distinguishing those patients that could benefit from therapy 
with SAMe (S-adenosyl methionine) [113].
Recently, studies in rodents suggest that epigenetic events, inheritable events not caused by 
changes in DNA sequence, may influence susceptibility to NASH. The three most commonly 
described epigenetic mechanisms are DNA (CpG) methylation, post-translational histone 
modifications and microRNAs (miRNAs). Several miRNAs have been identified in serum/
plasma of NAFLD patients that show diagnostic potential for distinguishing NAFL from 
NASH and advanced fibrosis [114].
4. Diagnosis of hepatic fibrosis
The stage of fibrosis ranges from absent (F0) to cirrhosis (F4), with stages F2–F4 considered to 
be clinically significant and stages F3–F4 considered to be advanced fibrosis. Apart from liver 
biopsy, there are two broad categories of non-invasive markers used to determine the stage of 
liver fibrosis: serum and radiological markers. This stratification based on markers of fibrosis 
is more tractable than those used for NASH and so it is currently used to identify patients 
who are at risk of disease progression.
4.1. Serum biomarkers
There are two large groups of predictive models of advanced fibrosis: ‘simple bedside mod-
els’, which use a combination of routine blood tests and clinical variables, and ‘complex 
models’, which use serum markers of fibrosis (measures of extracellular matrix deposition 
and turnover).
Although several of these predictive models of advanced fibrosis have been evaluated 
(Table 3) [61, 66, 115], two of the tests have been more widely studied and have easily avail-
able parameters, Fibrosis-4 index (FIB-4) and NAFLD Fibrosis Score (NFS). FIB-4 is based on 
age, levels of AST, ALT and platelet count. Values of this index below −1.30 enable the exclu-
sion of the presence of advanced fibrosis with a sensitivity of 74% and a specificity of 71%, 
while values above 2.67 indicate advanced fibrosis with a sensitivity and specificity of 33 and 
98%, respectively [115]. NFS is another formula developed and validated for the detection 
of advanced fibrosis that includes age, BMI, presence of diabetes or hyperglycemia, platelet 
count, albumin and AST/ALT ratio (http://nafldscore.com/). In a meta-analysis of 13 studies 
with more than 3000 patients, a value of NFS < −1.455 had a sensitivity of 90% and a specificity 
of 60% to exclude advanced fibrosis, while a value of >0.676 identified the presence of it with 
a sensitivity of 67% and a specificity of 97% [116].
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The principal drawback of all these biomarkers is that none of them is specific of the liver and 
their results can be influenced by co-morbidities of patients, so a critical interpretation of the 
result is necessary.
4.2. Imaging methods to measure fibrosis
With respect to image techniques, transient elastography (FibroScan®) is the most widely used 
technique in the diagnosis of liver fibrosis, not only in NAFLD but also in different chronic 
Model Variables Cut-offs Sensitivity (%) Specificity (%)
FIB-4 Age, AST and ALT 1.30 (low cut-off) 74 71
levels, platelets 2.67 (high cut-off) 33 98
NAFLD Age, hyperglycemia, −1.455 (low cut-off) 90 60
fibrosis score BMV, AST/ALT ratio, 0.675 (high cut-off) 67 97
albumin, platelet
AST to AST, platelet 1 27 89
platelet ratio
index (APRI)
AST/ALT ratio AST, ALT 0.8 (low cut-off) 90 60
1 (high cut-off) 67 97
BAAT score BMI, age, ALT, serum 2 71 80
triglycerides
BARD score BMI, AST/ALT ratio, 2 89 44
diabetes
Enhanced Age, hyaluronic acid, 8.5 (low cut-off) 80 90
liver fibrosis TIMP-1, PIIINP 11.3 (high cut-off)
(ELF) test
FibroTest α2-macroglobulin, 0.3 (low cut-off) 77 77
haptoglobin, GGT, 0.7 (high cut-off) 15 90
bilirubin,
apolipoprotein
Hepascore Age, gender, bilirubin, 0.44 75 84
hyaluronic acid, α2-
macroglobulin
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; TIMP-1, tissue inhibitor of 
metalloproteinase 1; PIIINP, procollagen III amino-terminal peptide; GGT, gamma glutamyl transferase.
Table 3. Predictive models for significant and advanced fibrosis in NAFLD patients.
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liver diseases [117]. TE measures the propagation velocity of low-frequency waves (50 Hz) 
through the hepatic parenchyma using ultrasounds and is expressed in kilo Pascal (kPa); the 
higher the propagation velocity, the greater the stiffness of the tissue. The advantages pro-
vided by this technique are its speed, the immediacy of the results and the ease of handling. 
However, proper results require careful interpretation of data, based on at least 10 success-
ful measurements, a success rate above 60% and an interquartile range (IQR) of <30% of the 
median value. A limitation of TE in NAFLD is the high rate of technical failure due to the 
attenuation of the elastic wave by interposition of adipose tissue secondary to the central 
obesity, very frequent in these patients. Although an XL probe has been developed, which 
enables greater penetration of the wave, this difficulty is often insurmountable [118, 119]. 
Moreover, this technique has been initially validated in patients with chronic infection by 
VHC [120], while the studies focusing on evaluating its use in NAFLD are smaller and have 
often used different cut-offs [42, 118, 121–129] (Table 4). According to the results of several 
studies, the cut-offs with M probe accepted for NAFLD patients are 7.0 kPa for significant 
fibrosis (≥F2), 8.7 kPa for advanced fibrosis (≥F3) and 10.3 kPa for cirrhosis (F4) [124, 126, 128]. 
When using the XL probe, these cut-offs differ as the measure of liver stiffness with this probe 
is less than that with the M probe in the same patient; in this case, 6.2, 7.2 and 7.9 kPa are the 
cut-offs for significant fibrosis, advanced fibrosis and cirrhosis, respectively [119, 130, 131].
Another liver elasticity-based imaging technique is ARFI (acoustic radiation force impulse  imaging). 
Although for the time being there are few studies that have evaluated its utility in NAFLD 
patients, its great advantage is that it can be easily connected to traditional ultrasound scan 
enabling the positioning of the zone of interest under visual control [132, 133]. Another method 
suitable for studying the elastic properties of the hepatic parenchyma is magnetic resonance 
elastography (MRE). MRE can be more reliable than TE to diagnose advanced fibrosis; more-
over, it has the advantage of being able to evaluate the whole hepatic parenchyma even in obese 
patients, but the technique is expensive and not widely available [134, 135]. Magnetic resonance 
imaging is more widely available and is the basis of new software called DEMILI (Detection of 
Metabolic-Induced Liver Injury), which through computerized optical analysis of its images deter-
mines a series of optical biomarkers enabling the detection of the presence of NASH (NASHMRI) 
and predicting significant fibrosis (FibroMRI) in NAFLD patients. For the detection of NASH, 
a cut-off has been established with NASHMRI of >0.5, presenting a sensitivity and specificity of 
87 and 60%, respectively. In the case of FibroMRI, the cut-off is also >0.5 for the prediction of sig-
nificant fibrosis with a sensitivity of 77% and a specificity of 80% [136]. Given that this technique 
enables the analysis of the total volume of the liver, as well as its use in the diagnosis of NASH 
and significant fibrosis, it enables the potential effects of a therapy to be monitored.
A recently developed technique is multiparametric magnetic resonance (MR) that includes T
1
 
mapping for fibrosis/inflammation imaging, T
2
∗ mapping for liver iron quantification and pro-
ton magnetic resonance spectroscopy (1H-MRS) for liver fat quantification. In a recent study, it 
has demonstrated good correlation with disease severity in NAFLD patients, showing excel-
lent accuracy in quantifying both the inflammatory and fibrotic components of NAFLD [137].
A summary of the approach to the management and characterization of NAFLD patients is 
shown in Figure 1.
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Study Patients, n Probe Fibrosis 
Stage
Cut-off (kPa) Sensitivity 
(%)
Specificity 
(%)
Yoneda et al. [122] 67 M F ≥ 2 6.65 82 91
F ≥ 3 8.0 87 84
F = 4 17.0 100 98
Yoneda et al. [125] 97 M F ≥ 2 6.65 74 97
F ≥ 3 9.8 85 81
F = 4 17.5 100 97
Nobili et al. [129] 52 M F ≥ 2 7.4 100 92
F ≥ 3 10.2 100 100
F = 4 –
Wong et al. [128] 246 M F ≥ 2 7.0 79 76
F ≥ 3 8.7 84 83
F = 4 10.3 92 88
Lupsor et al. [124] 72 M F ≥ 2 6.8 67 84
F ≥ 3 10.4 100 97
F = 4 –
Petta et al. [118] 169 M F ≥ 2 7.25 69 70
F ≥ 3 8.75 76 78
F = 4 –
Kumar et al. [126] 205 M F ≥ 2 7.0 78 79
F ≥ 3 9.0 85 88
F = 4 11.8 90 88
Pathik et al. [121] 110 M F ≥ 2 9.1 – –
F ≥ 3 12.0 90 80
F = 4 20.0 90 80
Cassinotto et al. [123] 291 M F ≥ 2 6.2 90 –
F ≥ 3 8.2 90 –
F = 4 9.5 90 –
Imajo et al. [42] 142 M F ≥ 2 11.0 62 100
F ≥ 3 11.4 86 84
F = 4 14.0 100 76
Table 4. Comparative studies of FibroScan with liver biopsy in the detection of fibrosis in NAFLD.
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5. Monitoring disease progression
A recent meta-analysis of 11 studies that evaluated the progression of NAFLD through the use 
of paired liver biopsies revealed that patients with NAFL and NASH presented a progression 
of fibrosis of 33.6% and an improvement of it of 22.3%, the rate of fibrosis progression being 
greater in patients with NASH than with NAFL (progression in a stage of 7.1 years compared 
to 14.3 years, respectively) [5]. However, there is a lack of homogenization in the speed of 
fibrosis progression in all these studies with paired biopsy, which is mostly due to the pres-
ence of characteristics of the metabolic syndrome in the patients [5–7, 62, 65, 138–144]. For this 
reason, due to the lack of studies that provide complete data about the differential progression 
of the disease in patients with different stages of NAFLD, there is no guide on the frequency of 
follow-up of these patients or on the means available to monitor the progression. Nevertheless, 
once the diagnosis of NAFLD is made, the follow-up will depend on the presence of metabolic 
risk factors and the severity of the hepatic disease, which will be determined by the presence 
of NASH and, especially, the stage of fibrosis.
The principal metabolic factor of the risk of NAFLD progression is DM2 [1, 19, 145]. Patients 
with DM2 have a more severe grade of NAFLD than the patients without DM2, with rates 
of NASH up to 80% and of advanced fibrosis of 30–40% [146, 147]. These data confirm the 
need for closer monitoring in these patients. Bazick et al. [147] developed a clinical model to 
detect NASH and advanced fibrosis in patients with NAFLD and DM2 with a sensitivity and 
specificity of 57 and 90%, respectively. This model includes easily accessible parameters such 
as BMI, circumference at the waist, HbA1c, insulin resistance, ALT, AST, albumin and fer-
ritin, for NASH; and age, BMI, waist/hip ratio, arterial hypertension, ALT/AST ratio, alkaline 
Figure 1. Practical approach to the management of patient with NAFLD.
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phosphatase, bilirubin, globulin, albumin, serum insulin, hematocrit, INR and platelets, to 
predict advanced fibrosis. However, further studies are still necessary to externally validate 
this model. Other metabolic factors described with more evidence for the disease progression 
are central obesity, arterial hypertension and high levels of LDL cholesterol [7, 148–150]. No 
study shows cost-efficacy in the monitoring of the progression in these at-risk patients, but 
we recommend carrying out NFS and/or FIB-4 every 2 or 3 years in these patients with non-
significant fibrosis, and if NASH and/or significant fibrosis is presented in the initial diagno-
sis, the follow-up will not differ from the rest of the patients.
The other factor having the greatest effect on the disease progression is liver fibrosis [151]. In 
general, in a period of 15 years, 13% of the patients with stage F2 and 25% of those present-
ing with F3 will develop cirrhosis [6, 7, 62]. These patients with significant fibrosis should be 
considered for pharmacological treatment, besides lifestyle modifications (diet and exercise). 
Moreover, NAFLD patients may develop HCC even in the absence of cirrhosis [152], given that 
it is the continuous hepatocyte injury that leads to a compensatory proliferation, key driver of 
the development of HCC [153]. Therefore, patients with NASH and significant fibrosis, which 
is indicative of important cellular damage, are also at risk of developing this liver tumor.
With all this information, we recommend recalculating NFS and/or FIB-4 every 4–5 years 
for patients with NAFL without risk factors or if the patient develops DM2; in patients with 
NASH without significant fibrosis, we recommend an annual follow-up with a calculation of 
NFS and/or FIB-4 and carrying out TE and ultrasound, and in patients with significant fibrosis, 
a 6-monthly follow-up is recommended with special interest in screening for HCC. The man-
agement and follow-up of the patients with advanced fibrosis/cirrhosis due to NASH does not 
differ from the rest of etiologies [25].
Another important question is the evaluation of the response to the therapy provided. The 
non-invasive methods available currently have not been reliable or have not been validated 
to document efficacy of the treatments, so liver biopsy is still necessary to determine this effi-
cacy, especially in a clinical trial setting.
6. Screening of associated diseases
In recent years, several studies have confirmed that the morbimortality associated with 
NAFLD is not limited only to hepatic injury, yet it is a disease with multisystemic behavior 
with affectation of different organs.
6.1. Insulin resistance and metabolic syndrome
As was previously mentioned, the concurrent characteristics of metabolic syndrome increase 
the risk of developing NAFLD, and a recent study of the HepaMet group relates the severity 
of NAFLD with the number of factors of the metabolic syndrome present (publication pend-
ing). However, the presence of NAFLD in itself also increases the risk of developing complica-
tions such as dyslipidemia and insulin resistance [154–156]. In this sense, the diagnosis and 
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quantification of hepatic fat can be useful in the prediction of future development of diabetes 
and other cardiovascular risk factors [56].
Insulin resistance is a key in the physiopathology of NAFLD, associated with the increase 
in the deposit of fat and fibrosis, and it substantially increases the risk of developing DM2, 
which indicates that NAFLD can precede the development of diabetes. Moreover, and as it 
was mentioned earlier, several studies have demonstrated that, especially in patients with 
insulin resistance and/or diabetes, liver fibrosis can progress even when a baseline hepatic 
histology described only simple steatosis without hepatocellular damage [62, 141]. All in all, 
in daily clinical practice the use of screening tools is necessary to detect the presence of dia-
betes (fasting blood glucose levels, HbA1c or, if available, the oral glucose tolerance test) or 
insulin resistance. The reference technique for the diagnosis of IR in non-diabetic patients is 
the hyperinsulinemic-euglycemic clamp test, although this procedure is expensive and com-
plicated, so it is not routinely used in daily clinical practice [157]. In these cases, the calcula-
tion of HOMA-IR (homeostatic model assessment) is an acceptable alternative to evaluate the 
IR, although there is no agreement on the threshold that defines insulin resistance using this 
formula [158]. Nevertheless, HOMA-IR can help us during the follow-up to identify patients 
at risk of fibrosis progression [6, 62]. The next question once the patients with IR are identi-
fied is whether it is necessary to treat them pharmacologically or not; and, whether in diabetic 
patients is necessary to intensify the anti-diabetic treatment to avoid liver disease progression 
or not. As expected, several insulin-sensitizing agents have demonstrated an improvement 
in the hepatic histology [159–161], even in patients without DM2 [162, 163], given that both 
entities share multiple physiopathological mechanisms, so this treatment can be considered in 
patients with NASH and/or multiple factors of progression in which a decrease of IR cannot 
be achieved with diet and exercise, although the EASL and AASLD guidelines do not contem-
plate it. Given that IR plays an essential role in NAFLD progression but not the only one, we 
do not believe that it is necessary to treat DM2 differently/intensely in patients with NAFLD, 
independently of the grade, provided that the IR is controlled.
6.2. Cardiovascular disease
Cardiovascular disease is quantitatively the main cause of death in NAFLD patients. Besides 
the risk itself of the characteristics of the metabolic syndrome, multiple pathogenic conditions 
of NAFLD contribute to the development of cardiovascular disease. In fact, patients with 
NAFLD often present elevation in the markers implicated in the development of atheroscle-
rosis, such as CD36 in its soluble form (sCD36), a membrane receptor responsible for, among 
other things, the transport of fatty acids [164]. The spectrum of CVD in NAFLD includes ath-
erosclerotic coronary heart disease, heart failure and cardiac arrhythmias. This necessitates 
the study of probable CVD, especially subclinical atherosclerosis, in all these patients [10]. 
There are little data to define the optimal means of screening NAFLD patients with CVD, but 
it is important to be aware that there are different techniques for the detection of subclinical 
atherosclerosis that are bloodless and some of which are very easily performed. Among these, 
the measurement of ankle-brachial index and carotid ultrasound are assessments especially 
useful for patients with intermediate cardiovascular risk, situation affecting a very important 
part of the population with NAFLD [165].
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6.3. Extrahepatic cancer
The second most prevalent cause of death among patients with NAFLD is cancer, both gas-
trointestinal (colon, esophagus, stomach and pancreas) and extraintestinal (kidney and 
breast), which leads to the suspicion that this liver disease might promote the development of 
neoplasms.
The association of insulin resistance/diabetes, obesity and metabolic syndrome with an 
increase in the risk of a large number of cancers is well established [166–171]. These three 
characteristics are closely related to NAFLD and contribute significantly to the risk of devel-
oping HCC; nevertheless, various recent studies indicate that NAFLD can be an additional 
and independent risk factor for extrahepatic cancers [172, 173], especially colorectal cancer 
(CRC) [127, 174]. In several studies, colorectal lesions, particularly tubular adenomas and 
carcinomas, were significantly more prevalent in NAFLD patients, regardless of age, sex and 
manifestations of metabolic syndrome; even the presence of NASH has been related to a 
greater risk in comparison with those with NAFL [174, 175]. This rise in the risk of CRC in 
NAFLD can be explained by the increase in insulin and pro-inflammatory cytokines and the 
alteration of the adipokines metabolism predominantly leptin versus adiponectin that exists 
in these patients and which promotes cellular proliferation, inhibition of apoptosis and angio-
genesis [176, 177].
Although these data clearly suggest more rigorous screening programmes for CRC in NAFLD 
patients, there are no well-designed prospective studies enabling the verification of a causal 
relation between NAFLD and CRC or studies that evaluate the usefulness of earlier screen-
ing in this liver disease, so no guidelines make a distinction with respect to CRC screening in 
these patients.
6.4. Other associated diseases
There is increasing interest in the possible contribution of NAFLD to the development and 
progression of chronic kidney disease (CKD) [178–181]. A recent meta-analysis has revealed 
that the presence and severity of NAFLD are associated with an increase in the risk and sever-
ity of CKD [181]. However, it is difficult to establish NAFLD as an independent risk factor of 
CKD given the close relation between NAFLD and other known risk factors of CKD such as 
obesity and IR. Obstructive sleep apnea syndrome (OSAS) is strongly associated with NAFLD 
independently of other traditional factors; it is a consequence of the decrease in the lipid 
metabolism provoked by intermittent hypoxia [182–185]. Other described diseases associated 
with NAFLD include osteoporosis [186], psoriasis [187], polycystic syndrome [188] and other 
endocrinopathies such as hypothyroidism [189], hypopituitarism [190] and hypogonadism 
[191]. Until now, there is no evidence for screening of all these pathologies for the mere fact 
that the subject presents NAFLD, so all that needs to be studied is the presence of them if the 
patient has clinical manifestations related to them. Moreover, a recent study by our group has 
demonstrated that psychotic patients with specific pharmacological treatment have a high 
risk of developing NAFLD in the first years, so its early detection will enable better prevention 
of cardiovascular events, which are so increased in this population [192].
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INITIAL DIAGNOSIS OF NAFLD
Transient Elastography + NFS
M probe < 7 kPa 
XL probe < 6.2 kPa 
+/- NFS < -1,455
M probe ≥ 7 kPa 
XL probe ≥ 6.2 kPa 
+/- NFS > 0.676
NAFL NASH
Follow-up by
primary care
physician. 
Recalculate NFS / 
FIB-4 every 4-5 
years (every 2-3 
years in paents
with metabolic risk
factors)
Annual
follow-up
OWLiver
Liver biopsy
+ DEMILI + 
OWLiver
F0-1 F2-3 F4
NAFL Semi-annual
follow-up. 
Screening 
for HCC
Screening for
HCC. Specific
management
NASH
Annual
follow-up
Figure 2. Clinical algorithm for the diagnosis of NAFLD and monitoring disease progression.
7. Diagnostic algorithm and follow-up
While working on the different sections of this chapter, we have detailed the fundamental ele-
ments for the development of a diagnostic algorithm and a follow-up procedure for NAFLD 
(Figure 2). This algorithm is based on clinical evidence available in the current literature with 
respect to the topic and on different guidelines issued by the principal international associa-
tions for the study of the liver (EASL and AASLD). In the case of monitoring and follow-up 
of these patients where the existing evidence is not relevant in certain aspects, our recom-
mendations are based on the experience of our clinical group in different high-quality studies 
in this field.
Once the initial diagnosis of NAFLD is made, our posterior attitude will depend on the result 
of the non-invasive liver fibrosis methods. In general, current image techniques are quite reli-
able to distinguish between advanced fibrosis (≥F3) and mild fibrosis or null (F0–F1), but they 
are insufficient to identify those patients with significant fibrosis (≥F2). Therefore, in clinical 
practice, we recommend the combination of elastographic techniques with serum markers, 
more specifically TE and NFS due to their wide accessibility and ease of application. When 
these two parameters generate doubt about the grade of fibrosis or indicate possible signifi-
cant fibrosis, liver biopsy is necessary. Depending on the result, we determine the posterior 
follow-up as can be seen in the algorithm (Figure 2). The presence of metabolic risk factors 
influences not only the therapeutic management but also the follow-up. If liver biopsy is 
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not to be performed on the patient with NAFLD, due to advanced age, to the absence of 
 significant fibrosis in the non-invasive methods or to contraindication, we could evaluate the 
performance of the OWL Liver Test to help identify those patients with NASH who require a 
closer follow-up. If the patient does not present improvement in laboratory parameters even 
in imaging tests, we should evaluate to repeat liver biopsy 5 years after the last one, or even 
before if progression of the disease is suspected.
8. Conclusions
NAFLD is currently the primary cause of chronic liver disease in the western world and its 
growth is a consequence of its close relation to obesity and metabolic syndrome. One of the 
great challenges in this disease is to diagnose and classify it correctly, given that the character-
istics defining NAFLD are the common denominator of many liver diseases. Its correct char-
acterization is important as in spite of presenting a generally benign and slowly developing 
evolution from the hepatic viewpoint; the fatty liver can progress towards more severe forms 
with the development of inflammation, fibrosis, cirrhosis and HCC, thus conferring morbi-
mortality. However, its potential morbimortality is not limited to this organ, but goes beyond; 
NAFLD is being considered a mediator of systemic diseases. Therefore, the early identification 
of these patients would help to improve its prognosis through an individualized intervention 
depending on the stage of liver disease, on the metabolic risk factors present and on the car-
diovascular risk, which translates into the need for a systemic approach to the disease with 
multidisciplinary management including primary care physician, endocrinologists, nutrition-
ists, psychologists and hepatologists.
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